{
  "id": "5e48bd2ed14c9f295d000017",
  "type": "yesno",
  "question": "Is ozanezumab effective for amyotrophic lateral sclerosis?",
  "ideal_answer": "No. Ozanezumab did not show efficacy compared with placebo in patients with amyotrophic lateral sclerosis. Therefore, Nogo-A does not seem to be an effective therapeutic target in ALS.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28139349"
  ],
  "snippets": [
    {
      "text": "The adjusted mean of the joint-rank score was -14\u00b79 (SE 13\u00b75) for the ozanezumab group and 15\u00b70 (13\u00b76) for the placebo group, with a least squares mean difference of -30\u00b70 (95% CI -67\u00b79 to 7\u00b79; p=0\u00b712). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Ozanezumab did not show efficacy compared with placebo in patients with ALS. Therefore, Nogo-A does not seem to be an effective therapeutic target in ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\n\nOzanezumab did not show efficacy compared with placebo in patients with ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The adjusted mean of the joint-rank score was -14\u00b79 (SE 13\u00b75) for the ozanezumab group and 15\u00b70 (13\u00b76) for the placebo group, with a least squares mean difference of -30\u00b70 (95% CI -67\u00b79 to 7\u00b79; p=0\u00b712).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Ozanezumab did not show efficacy compared with placebo in patients with ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The adjusted mean of the joint-rank score was -14\u00b79 (SE 13\u00b75) for the ozanezumab group and 15\u00b70 (13\u00b76) for the placebo group, with a least squares mean difference of -30\u00b70 (95% CI -67\u00b79 to 7\u00b79; p=0\u00b712).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28139349",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}